Compare BBVA & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBVA | BMY |
|---|---|---|
| Founded | 1857 | 1887 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.0B | 110.2B |
| IPO Year | N/A | N/A |
| Metric | BBVA | BMY |
|---|---|---|
| Price | $23.39 | $54.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $56.31 |
| AVG Volume (30 Days) | 1.2M | ★ 15.3M |
| Earning Date | 01-29-2026 | 02-05-2026 |
| Dividend Yield | 2.77% | ★ 4.75% |
| EPS Growth | ★ 7.95 | N/A |
| EPS | 2.04 | ★ 2.97 |
| Revenue | $37,116,038,958.00 | ★ $48,034,000,000.00 |
| Revenue This Year | $17.82 | $0.27 |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | ★ $11.72 | $17.86 |
| Revenue Growth | ★ 6.03 | 1.26 |
| 52 Week Low | $9.85 | $42.52 |
| 52 Week High | $24.19 | $63.33 |
| Indicator | BBVA | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 63.18 |
| Support Level | $23.31 | $52.06 |
| Resistance Level | $24.19 | $55.04 |
| Average True Range (ATR) | 0.30 | 0.92 |
| MACD | 0.00 | -0.26 |
| Stochastic Oscillator | 57.14 | 79.70 |
Despite its Spanish origins, Banco Bilbao Vizcaya Argentaria generates only around one-fourth of its profits in Spain. We expect that on a normalized basis, BBVA's market-leading Mexican bank should contribute half of its earnings, while its Turkish operation should account for another 15%. The balance of BBVA's earnings comes from smaller operations in South America. BBVA is overwhelmingly a retail and commercial bank, with corporate and investment banking forming a minor part of the overall business. BBVA also offers insurance and investment products through its banking networks.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.